Turning innovation into impact: Canada’s biotech advantage

Canada continues to struggle at turning research strength into economic growth. For a country with world-class science, this gap is more than a statistic, it’s a signal of both risk, and opportunity.
Industry Minister Mélanie Joly announced on Sept. 25 that Moderna produced the first made-in-Canada doses of its COVID-19 vaccine at its new mRNA vaccine biomanufacturing facility in Laval, Que.

Canada has long worn a badge of innovation proudly. For decades, we’ve brought healing therapies and new technologies to the world—insulin, avionics, gene editing—and, as seen most recently with the Nobel prize in Economics, novel ways to understand economic and i...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.


Already a Subscriber?

Get Innovation & Industry Newsletter

From investment to regulation, the policies, decisions and people working on industry and innovation. Tuesday.


By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

MORE Opinion

RELATED STORIES